BioMarin Pharmaceutical Inc. BMRN
55.66 USD -1.78 (-3.10%)
At closeNov 3, 2026, 4:00 PM EST
55.66 0.00 0.00%
After hours · Nov 3, 4:00 PM ET
52.00 Day range 56.32
49.26 52-week range 70.98
- YTD
- -6.34%
- 1 year
- +5.32%
Analyst view
Consensus: buy
Buy
Price target (mean) 91.33 +64.1% upside
Now 55.66
- Target (low)
- 60.00
- Target (mean)
- 91.33
- Target (high)
- 120.00
Ratings (0m) 28 21 buy · 7 hold · 0 sell
- Strong buy5
- Buy16
- Hold7
- Sell0
- Strong sell0
Recommendation trend
- This month 28
- 1 month ago 28
- 2 months ago 27
- 3 months ago 27
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.1123 | -0.48 – 0.24 | 0.12 | -193.6% | 1.10B | +25.8% | 15 |
| Next quarter | 1.44 | 1.29 – 1.71 | 0.46 | +212.7% | 1.06B | +38.2% | 7 |
| Current year | 3.16 | 2.85 – 3.37 | 3.15 | +0.3% | 3.88B | +20.5% | 8 |
| Next year | 6.39 | 4.14 – 7.17 | 3.16 | +102.1% | 4.46B | +15.0% | 13 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 3, 2026 | Morgan Stanley | Maintained | Overweight | Overweight |
| Nov 3, 2026 | Oppenheimer | Maintained | Outperform | Outperform |
| Nov 3, 2026 | HC Wainwright & Co. | Reiterated | Neutral | Neutral |
| Nov 3, 2026 | RBC Capital | Maintained | Sector Perform | Sector Perform |
| Nov 3, 2026 | Stifel | Maintained | Hold | Hold |
| Oct 21, 2026 | Morgan Stanley | Maintained | Overweight | Overweight |
| Oct 20, 2026 | JP Morgan | Maintained | Overweight | Overweight |
| Oct 20, 2026 | Cantor Fitzgerald | Reiterated | Overweight | Overweight |
| Oct 14, 2026 | Barclays | Maintained | Overweight | Overweight |
| Sep 10, 2026 | HC Wainwright & Co. | Reiterated | Neutral | Neutral |
| Sep 1, 2026 | Piper Sandler | Maintained | Overweight | Overweight |
| Aug 31, 2026 | Jefferies | Maintained | Buy | Buy |
| Aug 31, 2026 | HC Wainwright & Co. | Maintained | Neutral | Neutral |
| Aug 19, 2026 | BMO Capital | Initiated | Outperform | Outperform |
| Aug 18, 2026 | HC Wainwright & Co. | Maintained | Neutral | Neutral |
| Aug 17, 2026 | Piper Sandler | Maintained | Overweight | Overweight |
| Aug 17, 2026 | Barclays | Maintained | Overweight | Overweight |
| Aug 10, 2026 | Canaccord Genuity | Maintained | Buy | Buy |
| Aug 7, 2026 | Morgan Stanley | Maintained | Overweight | Overweight |
| Aug 7, 2026 | Oppenheimer | Maintained | Outperform | Outperform |
| Aug 7, 2026 | HC Wainwright & Co. | Maintained | Neutral | Neutral |
| Jul 16, 2026 | Citigroup | Maintained | Buy | Buy |
| Jul 7, 2026 | RBC Capital | Maintained | Sector Perform | Sector Perform |
| May 22, 2026 | Canaccord Genuity | Maintained | Buy | Buy |
| May 19, 2026 | B of A Securities | Maintained | Buy | Buy |
| May 19, 2026 | Citigroup | Initiated | — | Buy |
| May 18, 2026 | HC Wainwright & Co. | Maintained | Neutral | Neutral |
| May 7, 2026 | Canaccord Genuity | Maintained | Buy | Buy |
| May 5, 2026 | Bernstein | Maintained | Outperform | Outperform |
| May 5, 2026 | Morgan Stanley | Maintained | Overweight | Overweight |
